Omentin as a novel biomarker of metabolic risk factors

Diabetology & Metabolic Syndrome

Toyoaki Murohara⁴  Shinji Kihara¹  Hiroko Terasaki¹  Akiko Higuchi³  Nobuo Ikeda⁵  Koji Ohashi²  Yuya Terakura⁴  Ryotaro Takahashi⁵  Noriyuki Ouchi²  Rei Shibata⁴ 

[1] Department of Biomedical Informatics, Osaka University Graduate School of Medicine, Nagoya, Japan;Department of Molecular Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-Ku, Nagoya, 466-8550, Japan;Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan;Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan;Department of Cardiology, Chunichi Hospital, Nagoya, Japan

关键词: Biomarkers;    Risk factors;    Metabolic disorders;    Adipocytokine;    Omentin;   

Others  :  814893
DOI  :  10.1186/1758-5996-4-37

 received in 2012-03-28, accepted in 2012-07-26,  发布年份 2012

【 摘 要 】

Background

Omentin is an adipocytokine that is abundantly expressed in visceral fat tissue. We investigated the association of omentin with the number of metabolic risk factors.

Finding

The study population comprised 201 Japanese men who underwent annual health checkups. Plasma omentin levels were determined by enzyme-linked immunosorbent assay. We divided the subjects into 4 groups according to omentin levels. A reduction of plasma omentin levels significantly correlated with an increase in the mean number of metabolic risk factors such as increased waist circumference, dyslipidemia, high blood pressure and glucose intolerance.

Conclusions

Circulating omentin levels negatively correlated with the multiplicity of metabolic risk factors, suggesting that omentin acts as a biomarker of metabolic disorders.

【 授权许可】

   
2012 Shibata et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the united states: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord. 1998, 22:39-47.
• [2]Nielsen S, Jensen MD: Obesity and cardiovascular disease: Is body structure a factor? Curr Opin Lipidol 1997, 8:200-204.
• [3]Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 2006, 444:881-887.
• [4]Matsuzawa Y: Therapy insight: Adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2006, 3:35-42.
• [5]Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011, 11:85-97.
• [6]Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K: Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 2003, 14:561-566.
• [7]Shibata R, Ouchi N, Murohara T: Adiponectin and cardiovascular disease. Circ J 2009, 73:608-614.
• [8]Walsh K: Adipokines, myokines and cardiovascular disease. Circ J 2009, 73:13-18.
• [9]Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: Possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006, 290:E1253-E1261.
• [10]Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, Buchler C: Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 2005, 1732:96-102.
• [11]Tsuji S, Uehori J, Matsumoto M, Suzuki Y, Matsuhisa A, Toyoshima K, Seya T: Human intelectin is a novel soluble lectin that recognizes galactofuranose in carbohydrate chains of bacterial cell wall. J Biol Chem 2001, 276:23456-23463.
• [12]de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007, 56:1655-1661.
• [13]Pan HY, Guo L, Li Q: Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010, 88:29-33.
• [14]Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, Lehnert H, Randeva HS: Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 2008, 57:801-808.
• [15]Yamawaki H, Tsubaki N, Mukohda M, Okada M, Hara Y: Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels. Biochem Biophys Res Commun 2010, 393:668-672.
• [16]Shibata R, Takahashi R, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T, Ouchi N: Association of a fat-derived plasma protein omentin with carotid artery intima-media thickness in apparently healthy men. Hypertens Res 2011, 34:1309-1312.
• [17]Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, Chen FQ, Shang DY: Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011, 32:873-878.
• [18]Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, Ohashi K, Ikeda N, Kihara S, Murohara T: Circulating omentin is associated with coronary artery disease in men. Atherosclerosis 2011, 219(2):811-4.